Robert Peach

Dr. Peach has 30 years of drug discovery and development experience in the pharmaceutical and biotechnology industry. Robert co-founded Receptos, becoming Chief Scientific Officer and raising $59M in venture capital and $800M in an IPO. Receptos was acquired in 2015 by Celgene for $7.8B. Robert held senior executive and scientific positions in other companies including Apoptos (co-founder), Biogen Idec, IDEC Pharmaceuticals and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments. His extensive drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 4 registered drugs. He currently serves on the Board of Directors of Amplia Therapeutics, AdAlta and ReKover Therapeutics, and has been a Scientific Advisory Board member and consultant for several other biotechnology companies.